Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA7 | P43166 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821387 | 0.90 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2994444 | 0.86 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22468902 | 0.86 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1814266 | 0.84 | TSHR (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31700926 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17022287 | 0.84 | ALDH1A1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL137202 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30294343 | 0.84 | TSHR (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29843135 | 0.84 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL321387 | 0.84 | CA12 (0.62) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016184652-A9 | METHODS FOR PRODUCING METALATED ORGANIC COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016184652-A1 | METHODS FOR PRODUCING METALATED ORGANIC COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-11-24 | — | — | WO | disclosed |
| EP-2360161-B1 | Preparation and use of magnesium amides | MUNICHEM GMBH (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513416-B2 | Bisamide-zinc bases | LUDWIG-MAXIMILIANS-UNIVERSITAT MUENCHEN (DE) | 2013-08-20 | — | — | US | disclosed |
| US-8513416-B2 | Bisamide-zinc bases | LUDWIG-MAXIMILIANS-UNIVERSITAT MUENCHEN (DE) | 2013-08-20 | — | — | US | disclosed |
| US-8134005-B2 | Preparation and use of magnesium amides | Ludwig-Maximilians-Universitat München (DE) | 2012-03-13 | — | — | US | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100160632-A1 | BISAMID-ZINKBASEN | LUDWIG MAXIMILIANS UNIVERSITAT MUNCHEN | 2010-06-24 | — | — | US | disclosed |
| EP-0442748-B1 | Improvements in and relating to leukotriene antagonists | LILLY CO ELI (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0442748-A1 | Improvements in and relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1991-08-21 | — | — | EP | disclosed |
| US-4996230-A | Antiallergens, antiinflammatory agent | ELI LILLY AND COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| US-3989721-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3989720-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3988352-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-10-26 | — | — | US | disclosed |
| US-3979414-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3965115-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3963752-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3951618-A | Method of use of, and compositions containing, disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160632-A1 | BISAMID-ZINKBASEN | ZFX, ZRANB2, MLX | CA12 318/4885CA1 1208/4885CA2 370/4885 |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | CA12 2807/4885CA1 3037/4885CA2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.